RESEARCH AREA

Glioblastoma Multiforme (GB)

This is some text inside of a div block.

Completed Trials

2017: Avelumab in patients with newly diagnosed GBM (Phase II)

Future Trial

This is some text inside of a div block.

Glioblastoma Multiforme

GBM typically presents with headaches, new onset seizures, nausea, vomiting or cognitive dysfunction. Median survival without treatment is approximately six months. Conventional therapy consisting of surgery, radiotherapy, and Temozolomide chemotherapy extends median survival to 14 months.

At CNO

We offer a multidisciplinary approach to patients with GBM. Our neurologists in conjunction with other specialists; oncologists and neurosurgeons are involved in the diagnosis and medical treatment of the tumor and its complications such as seizures. Motor deficits affecting ambulation can be improved with neuro rehab via our in house NeuroGym.

Experimental treatments can be accessed via our clinical trials unit. CNO previously initiated and conducted a clinical trial which looked at combining immunotherapy with conventional therapies (Avelumab in Newly Diagnosed Glioblastoma Multiforme-the SEJ Study).

CNO is currently looking at using non-invasive neuromodulation (NINM) via repetitive transcranial magnetic stimulation (rTMS) to improve outcomes in patients with GBM.
CNO offers a multidisciplinary approach to patients with GBM. Our neurologists in conjunction with other specialists; oncologists and neurosurgeons are involved in the diagnosis and medical treatment of the tumor and its complications such as seizures, our patients benefit from personalized neurorehabilitation through our in-house NeuroGym rehabilitation program, designed to help improve motor deficits affecting ambulation.
CNO is currently looking at using non invasive neuromodulation (NNIM) via repetitive transcranial magnetic stimulation (rTMS) to improve outcomes in patients with GBM.
Experimental treatments can be accessed via our clinical trials. CNO previously initiated and conducted a clinical trial which looked at combining immunotherapy with conventional therapies.